Antibody therapeutics companies develop engineered antibodies that target specific molecules involved in disease. These medicines are used across oncology, autoimmune disease, inflammatory conditions, infectious disease and other areas of clinical development.
This category includes companies working on:
Browse 69 UK antibody therapeutics companies below.
Antigenic immunomodulation therapies targeting autoimmune disease
Phaim Pharma is a biotech company developing disease-modifying therapeutics for autoimmune conditions using its proprietary platform. The platform is designed to reset the immune…
Antibody discovery biotech targeting GPCRs in inflammatory disease
DJS Antibodies is a biotechnology company developing monoclonal antibody therapeutics against G protein-coupled receptors and other previously intractable disease targets. Its…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform…
AI-designed aptamer therapeutics for undruggable targets
PentaBind is a TechBio company using generative AI to design aptamers with drug-like properties for targets that are inaccessible to conventional modalities. Its platform combines…
Intranasal anti-CD3 antibody therapies for neurodegenerative diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapeutics for neurodegenerative and autoimmune diseases. Its lead candidate,…
Macrophage-targeting immuno-oncology therapies for solid tumours
Macomics is an immuno-oncology company developing precision medicines that modulate tumour-associated macrophages to enhance immune responses against cancer. Founded by University…
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset,…
Global biopharma with UK R&D centre on the Wirral Peninsula
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company with a long-established UK R&D site at Moreton on the Wirral Peninsula and its UK and Ireland commercial…
Clinical-stage rare disease biotech acquiring deprioritised pharma assets
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Founded in 2015, its business model centres on acquiring…
Proprietary phage display platform for therapeutic antibody discovery
RxBiologics is a Cambridge-based antibody discovery CRO and subsidiary of RxCelerate. Its proprietary phage display library platform incorporates in-line optimisation technology…
Engineered biologics with conditional activation for precision cancer immunotherapy
Switch Biologics is a UK biotechnology company developing engineered protein biologics for cancer immunotherapy. The company applies directed evolution and protein engineering to…